A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.
Chugai obtains Japanese regulatory approval for Tecentriq for additional indication of alveolar soft part sarcoma, an ultra-rare disease: Tokyo Friday, February 21, 2025, 10:00 Hr ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback